Silexion Advances KRAS Cancer Drug into Phase 2/3 Trials with Manufacturing and Regulatory Milestones
Event summary
- Silexion initiated GMP clinical supply manufacturing of SIL204 with Catalent at its Limoges, France facility.
- Tel Aviv Sourasky Medical Center approved Phase 2/3 trial for SIL204 in locally advanced pancreatic cancer.
- Israeli Ministry of Health approved the trial, with German CTA submission ongoing.
- SIL204 combines intratumoral and systemic delivery to target primary and metastatic pancreatic cancer.
The big picture
Silexion's progress reflects the growing focus on RNAi therapies for KRAS-driven cancers, a historically challenging target. The company's ability to secure both manufacturing and regulatory milestones positions it among the few advancing next-generation siRNA treatments into late-stage trials. Success here could validate the dual-route delivery strategy and attract partnerships in the competitive oncology space.
What we're watching
- Regulatory Momentum
- Whether Silexion can sustain multi-jurisdictional approvals for SIL204 trials.
- Manufacturing Execution
- The pace at which Catalent can deliver GMP-compliant clinical batches for patient dosing.
- Clinical Strategy
- How the dual-route administration approach will impact SIL204's efficacy in Phase 2/3 trials.
Related topics